Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 18/20 | 0.76 |
| ▸ | IDH1 | O75874 | 1/20 | 0.50 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4506906 | 1.00 | PTGDR2 (0.76) | PTGDR2IDH1PTGDRALDH1A1LMNA | |
| SCHEMBL13816522 | 1.00 | PTGDR2 (0.76) | PTGDR2IDH1PTGDRALDH1A1LMNA | |
| SCHEMBL5562838 | 0.85 | PTGDR2 (0.82) | PTGDR2SMN1; SMN2 | |
| SCHEMBL4513388 | 0.84 | PTGDR2 (1.00) | PTGDR2PTGDR | |
| SCHEMBL4514070 | 0.84 | PTGDR2 (0.81) | PTGDR2PTGDR | |
| SCHEMBL4506517 | 0.80 | PTGDR2 (1.00) | PTGDR2PTGDR | |
| SCHEMBL4492871 | 0.79 | PTGDR2 (1.00) | PTGDR2PTGDR | |
| SCHEMBL4507418 | 0.77 | PTGDR2 (0.75) | PTGDR2PTGDRALDH1A1LMNA | |
| SCHEMBL13816372 | 0.76 | PTGDR2 (0.86) | PTGDR2PTGDR | |
| SCHEMBL4502046 | 0.75 | PTGDR2 (1.00) | PTGDR2PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541383-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20080085891-A1 | Asthma and allergic inflammation modulators | FU ZICE | 2008-04-10 | — | — | US | disclosed |
| US-7321001-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-20040220237-A1 | Asthma and allergic inflammation modulators | AMGEN INC. | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085891-A1 | Asthma and allergic inflammation modulators | IL5, TSLP, CYSLTR2 | PTGDR2 200/4885IDH1 4826/4885PTGDR 185/4885 |
| US-20040220237-A1 | Asthma and allergic inflammation modulators | IL5, TSLP, CYSLTR2 | PTGDR2 200/4885IDH1 4826/4885PTGDR 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.